

Rui Feng

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9179350/publications.pdf>

Version: 2024-02-01

38
papers

551
citations

687363

13
h-index

677142

22
g-index

39
all docs

39
docs citations

39
times ranked

800
citing authors

#	ARTICLE	IF	CITATIONS
1	Systematic Review and Meta-analysis: Short-Chain Fatty Acid Characterization in Patients With Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2019, 25, 1751-1763.	1.9	73
2	Human induced pluripotent stem cell-derived mesenchymal stem cells promote healing via TNF- α -stimulated gene-6 in inflammatory bowel disease models. <i>Cell Death and Disease</i> , 2019, 10, 718.	6.3	51
3	E3 Ubiquitin ligase RNF183 Is a Novel Regulator in Inflammatory Bowel Disease. <i>Journal of Crohn's and Colitis</i> , 2016, 10, 713-725.	1.3	44
4	Systematic review and meta-analysis: Association of a pre-illness Western dietary pattern with the risk of developing inflammatory bowel disease. <i>Journal of Digestive Diseases</i> , 2020, 21, 362-371.	1.5	40
5	Circulating microRNA146b-5p is superior to C-reactive protein as a novel biomarker for monitoring inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 733-743.	3.7	32
6	Systematic review with meta-analysis: the efficacy and safety of stem cell therapy for Crohn's disease. <i>Stem Cell Research and Therapy</i> , 2017, 8, 136.	5.5	30
7	Systematic review with meta-analysis: environmental and dietary differences of inflammatory bowel disease in Eastern and Western populations. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 266-276.	3.7	30
8	Fecal Microbiota Alterations Associated With Clinical and Endoscopic Response to Infliximab Therapy in Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2020, 26, 1636-1647.	1.9	23
9	MALAT1 Maintains the Intestinal Mucosal Homeostasis in Crohn's Disease via the miR-146b-5p-CLDN11/NUMB Pathway. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 1542-1557.	1.3	20
10	Cytokine IL9 Triggers the Pathogenesis of Inflammatory Bowel Disease Through the miR21-CLDN8 Pathway. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 2211-2223.	1.9	16
11	Different clinical outcomes in Crohn's disease patients with esophagogastroduodenal, jejunal, and proximal ileal disease involvement: is L4 truly a single phenotype?. <i>Therapeutic Advances in Gastroenterology</i> , 2018, 11, 175628481877793.	3.2	16
12	Thalidomide induces clinical remission and mucosal healing in adults with active Crohn's disease: a prospective open-label study. <i>Therapeutic Advances in Gastroenterology</i> , 2017, 10, 397-406.	3.2	14
13	DNA Damage-Regulated Autophagy Modulator 1 (DRAM1) Mediates Autophagy and Apoptosis of Intestinal Epithelial Cells in Inflammatory Bowel Disease. <i>Digestive Diseases and Sciences</i> , 2021, 66, 3375-3390.	2.3	14
14	Dietary inflammatory potential mediated gut microbiota and metabolite alterations in Crohn's disease: A fire-new perspective. <i>Clinical Nutrition</i> , 2022, 41, 1260-1271.	5.0	14
15	Mucosal Healing Is Associated With the Reduced Disabling Disease in Crohn's Disease. <i>Clinical and Translational Gastroenterology</i> , 2019, 10, e00015.	2.5	13
16	Risk Factors Associated with Impaired Ovarian Reserve in Young Women of Reproductive Age with Crohn's Disease. <i>Intestinal Research</i> , 2020, 18, 200-209.	2.6	13
17	Gut Microbiota Profiles and Microbial-Based Therapies in Post-operative Crohn's Disease: A Systematic Review. <i>Frontiers in Medicine</i> , 2020, 7, 615858.	2.6	12
18	Index-Based Dietary Patterns and Inflammatory Bowel Disease: A Systematic Review of Observational Studies. <i>Advances in Nutrition</i> , 2021, 12, 2288-2300.	6.4	12

#	ARTICLE	IF	CITATIONS
19	Systematic review with meta-analysis of partial enteral nutrition for the maintenance of remission in Crohn's disease. <i>Nutrition Research</i> , 2020, 81, 7-18.	2.9	10
20	A New Model Based on 25-Hydroxyvitamin D3 for Predicting Active Crohn's Disease in Chinese Patients. <i>Mediators of Inflammation</i> , 2018, 2018, 1-8.	3.0	9
21	Down-Regulation of Colonic ACE2 Expression in Patients With Inflammatory Bowel Disease Responding to Anti-TNF Therapy: Implications for COVID-19. <i>Frontiers in Medicine</i> , 2020, 7, 613475.	2.6	9
22	Prolonged azathioprine treatment reduces the need for surgery in early Crohn's disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 664-670.	2.8	8
23	Co-culture of Gastric Organoids and Immortalized Stomach Mesenchymal Cells. <i>Methods in Molecular Biology</i> , 2016, 1422, 23-31.	0.9	7
24	Factors associated with the achievement of mucosal healing in Crohn's disease: the benefit of endoscopic monitoring in treating to target. <i>Therapeutic Advances in Gastroenterology</i> , 2017, 10, 453-463.	3.2	7
25	Heat shock protein family A member 6 combined with clinical characteristics for the differential diagnosis of intestinal Behçet's disease. <i>Journal of Digestive Diseases</i> , 2018, 19, 350-358.	1.5	7
26	Low 6-thioguanine nucleotide level: Effective in maintaining remission in Chinese patients with Crohn's disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019, 34, 679-685.	2.8	6
27	Epstein-Barr virus infection in ulcerative colitis: a clinicopathologic study from a Chinese area. <i>Therapeutic Advances in Gastroenterology</i> , 2020, 13, 175628482093012.	3.2	5
28	Can fecal calprotectin accurately identify histological activity of ulcerative colitis? A meta-analysis. <i>Therapeutic Advances in Gastroenterology</i> , 2021, 14, 175628482199474.	3.2	3
29	Differential Diagnosis of Crohn's Disease and Ulcerative Primary Intestinal Lymphoma: A Scoring Model Based on a Multicenter Study. <i>Frontiers in Oncology</i> , 2022, 12, 856345.	2.8	3
30	CYP2C19 polymorphism has no correlation with the efficacy and safety of thalidomide in the treatment of immune-related bowel disease. <i>Journal of Digestive Diseases</i> , 2020, 21, 98-103.	1.5	2
31	Serum biomarkers of fibrostenotic Crohn's disease: Where are we now?. <i>Journal of Digestive Diseases</i> , 2020, 21, 336-341.	1.5	2
32	Mucosal healing and quality of life in therapeutic goals of ulcerative colitis: occurrence and related factors of functional bowel disorder-like symptoms. <i>Therapeutic Advances in Gastroenterology</i> , 2022, 15, 175628482210925.	3.2	2
33	Childhood antibiotics as a risk factor for Crohn's disease: The <scp>ENIGMA</scp> International Cohort Study. <i>JGH Open</i> , 0, , .	1.6	2
34	Thiopurines prevented surgical recurrence in patients with Crohn's disease after intestinal resection: Strategy based on risk stratification. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 608-614.	2.8	1
35	Thalidomide Combined With Azathioprine as Induction and Maintenance Therapy for Azathioprine-Refractory Crohn's Disease Patients. <i>Frontiers in Medicine</i> , 2020, 7, 557986.	2.6	1
36	IDDF2018-ABS-0196...Exosomes derived from human iPSC-MSCS protected against TNBS-INDUCED colitis. , 2018, , .		0

#	ARTICLE	IF	CITATIONS
37	IDDF2019-ABS-0105...Systematic review with meta-analysis: partial enteral nutrition for maintenance of remission in crohn's disease. , 2019, , .		0
38	IDDF2019-ABS-0336...Systematic review with meta-analysis: the efficacy of methotrexate in ulcerative colitis. , 2019, , .		0